Other Clinical Trial - Special Investigation of Pregabalin for

Clinical Trial Description

All the patients whom an investigator prescribes the first pregabalin should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random. ;

Study Design

Related Conditions & MeSH terms

Fibromyalgia
Myofascial Pain Syndromes
Pain Associated With Fibromyalgia

See also
Status	Clinical Trial	Phase
Completed	`NCT02146430` - Treatment of Pain Associated With Fibromyalgia	Phase 3
Completed	`NCT02187159` - Treatment of Pain Associated With Fibromyalgia	Phase 3
Completed	`NCT02187471` - Treatment of Pain Associated With Fibromyalgia	Phase 3
Completed	`NCT02234583` - An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia	Phase 3

See also

Status

Clinical Trial

Phase

Completed

NCT02146430 - Treatment of Pain Associated With Fibromyalgia

Phase 3

Completed

NCT02187159 - Treatment of Pain Associated With Fibromyalgia

Phase 3

Completed

NCT02187471 - Treatment of Pain Associated With Fibromyalgia

Phase 3

Completed

NCT02234583 - An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia

Phase 3

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT01773993
Study type	Observational
Source	Pfizer
Contact
Status	Completed
Phase
Start date	February 2013
Completion date	July 2017

Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms